Organon affirms 2023 revenue and Adjusted EBITDA guidance and provides 2024 outlook

 Regular dividend to remain primary capital allocation priority

• For full year 2023, the company expects revenue and Adjusted EBITDA margin to be within the ranges provided on November 2, 2023
• For full year 2023 the company expects free cash flow before one-time spin-related costs to be above previously provided range
• For full year 2024, the company expects revenue to grow in the low-single-digit range on a constant currency basis, and to achieve stable to improving Adjusted EBITDA margin
• The company’s annual dividend of $1.12 per share remains its primary capital allocation priority, followed by a balance of discretionary debt repayment and opportunistic business development

https://www.businesswire.com/news/home/20240108542270/en/